<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Congenital long QT syndrome: Pathophysiology and genetics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Congenital long QT syndrome: Pathophysiology and genetics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Congenital long QT syndrome: Pathophysiology and genetics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael J Ackerman, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter J Schwartz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K Triedman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Samuel Asirvatham, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Todd F Dardas, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 03, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Long QT syndrome (LQTS) is a disorder of ventricular myocardial repolarization characterized by a prolonged QT interval on the electrocardiogram (ECG)  (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 1
         </a>
         ) that can lead to symptomatic ventricular arrhythmias and an increased risk of sudden cardiac death (SCD) [
         <a href="#rid1">
          1,2
         </a>
         ]. The primary symptoms in patients with LQTS include syncope, seizures, aborted cardiac arrest, and SCD. LQTS is associated with an increased risk of a characteristic life-threatening cardiac arrhythmia known as torsades de pointes (TdP) or "twisting of the points"  (
         <a class="graphic graphic_waveform graphicRef53891 graphicRef73827" href="/z/d/graphic/53891.html" rel="external">
          waveform 2A-B
         </a>
         ) [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p>
         LQTS may be congenital or acquired [
         <a href="#rid1">
          1,5
         </a>
         ]. Pathogenic variants in at least 17 LQTS-susceptibility genes have been identified thus far  (
         <a class="graphic graphic_table graphicRef114927" href="/z/d/graphic/114927.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef120655" href="/z/d/graphic/120655.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. However, pathogenic variants in the three canonical genes,
         <em>
          KCNQ1
         </em>
         (previously called
         <em>
          KVLQT1
         </em>
         , LQT1),
         <em>
          KCNH2
         </em>
         (previously called
         <em>
          HERG
         </em>
         ,
         <em>
         </em>
         LQT2), and
         <em>
          SCN5A
         </em>
         (LQT3), account for at least 75 to 80 percent of all LQTS, with disease-causative variants in the minor LQTS-susceptibility genes contributing only another 5 percent. Less than 15 to 20 percent of patients satisfying a robust clinical diagnosis of LQTS will have a negative, contemporary LQTS genetic test. Acquired LQTS usually results from undesired QT prolongation and potential for QT-triggered arrhythmias by either QT-prolonging disease states, QT-prolonging medications (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.crediblemeds.org%2F&amp;token=F2fTJXWTbAdqtiUVhUGfEeHvm%2Bapw8j0DIpr7ZimhTcQDLZbSKKNNIJ4B%2FwprPZ%2F&amp;TOPIC_ID=1009" target="_blank">
          www.crediblemeds.org
         </a>
         ), or QT-prolonging electrolyte disturbances  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         The pathophysiology and genetics of congenital LQTS will be reviewed here. Other aspects of LQTS are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Congenital LQTS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical features – (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diagnosis – (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment – (See
         <a class="medical medical_review" href="/z/d/html/988.html" rel="external">
          "Congenital long QT syndrome: Treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LQTS genes – (See
         <a class="medical medical_review" href="/z/d/html/128462.html" rel="external">
          "Gene test interpretation: Congenital long QT syndrome genes (
          <i>
           KCNQ1
          </i>
          ,
          <i>
           KCNH2
          </i>
          ,
          <i>
           SCN5A
          </i>
          )"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acquired LQTS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Causes – (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnosis and management – (See
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H179860788">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the relatively simple clinical definition of LQTS applies to both acquired and the variety of congenital forms, the pathophysiology of the disorder is complex, incompletely understood, and probably varies among patients. Two leading pathophysiologic hypotheses have emerged to explain commonly observed features of LQTS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extensive and growing clinical and genetic evidence supports the importance of perturbations in cardiac ion channels, resulting in prolongation of the action potential  (
         <a class="graphic graphic_figure graphicRef120655" href="/z/d/graphic/120655.html" rel="external">
          figure 1
         </a>
         ). Based on these data, congenital LQTS is considered a disease of ion channels and is the most common "cardiac channelopathy."
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The observation that the immediate trigger for torsades de pointes (TdP) in the inherited form is often a sudden surge in sympathetic tone (a feature not seen in the acquired form) led to the hypothesis that the congenital LQTS may be caused by an imbalance in the sympathetic innervation of the heart.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H973343666">
         <span class="h2">
          Perturbations in ion channels
         </span>
         <span class="headingEndMark">
          —
         </span>
         The established pathogenic basis for the vast majority of congenital LQTS involves perturbations in three critical ion channels of the heart. Loss-of-function mutations in the
         <em>
          KCNQ1-
         </em>
         encoded Kv7.1 potassium channel (phase 3 I
         <sub>
          Ks
         </sub>
         ) and
         <em>
          KCNH2-
         </em>
         encoded Kv11.1 potassium channels (phase 3 I
         <sub>
          Kr
         </sub>
         ) cause prolongation in the action potential duration at the cellular level and hence QT prolongation for at least two-thirds of all patients with LQTS. Gain-of-function mutations in the
         <em>
          SCN5A-
         </em>
         encoded Nav1.5 sodium channel account for approximately 5 to 10 percent of LQTS; they prolong the action potential duration by accentuating the sodium channel's late current or its window current. This action potential prolongation at the ventricular cardiac cell level sets up the increased vulnerability for early afterdepolarizations (EADs) and triggered activity via re-entrant mechanisms, which then produces torsadogenic syncope, seizure, or worse. (See
         <a class="local">
          'Prolonged repolarization and early afterdepolarizations'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H79497921">
         <span class="h3">
          The normal action potential
         </span>
         <span class="headingEndMark">
          —
         </span>
         An understanding of normal cardiac cell electrophysiology is required in order to fully appreciate the known perturbations in ion channels and their associated ion currents, and the electrophysiologic mechanisms that cause congenital LQTS. The normal action potential is composed of the following five phases, beginning with phase 4  (
         <a class="graphic graphic_figure graphicRef71390" href="/z/d/graphic/71390.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_movie graphicRef61058" href="/z/d/graphic/61058.html" rel="external">
          movie 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phase 4 (resting membrane potential)
         </strong>
         – Phase 4 represents the normal diastolic resting membrane potential of myocardial cells. The resting membrane potential of myocardial ventricular cell membranes during diastole is approximately -85 to -90 mV, which largely represents the equilibrium membrane potential for potassium in healthy states. This occurs because of the inwardly rectifying potassium channel Kir2.1 (I
         <sub>
          K1
         </sub>
         current) that is encoded by
         <em>
          KCNJ2.
         </em>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phase 0 (depolarization)
         </strong>
         – Phase 0 occurs when the membrane potential reaches approximately -70 mV. A rapid inward flow of sodium ions (I
         <sub>
          Na
         </sub>
         ) through the fast Nav1.5 sodium channels (encoded by
         <em>
          SCN5A
         </em>
         ) ensues and depolarizes the cell membrane. Inward current during phase 0 is also sustained by activation of L- and T-type calcium channels (I
         <sub>
          Ca-L
         </sub>
         and I
         <sub>
          Ca-T
         </sub>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phase 1 (initial repolarization)
         </strong>
         – Phase 1 represents an initial repolarization after the overshoot of phase 0 and is caused by a transient outward potassium current (I
         <sub>
          to1
         </sub>
         ) from the
         <em>
          KCND3-
         </em>
         encoded Kv4.3 potassium channels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phase 2 (plateau phase)
         </strong>
         – Phase 2 is called the plateau phase, because it represents an equilibrium between the inward calcium (I
         <sub>
          Ca-L
         </sub>
         /Cav1.2 encoded by
         <em>
          CACNA1C
         </em>
         and I
         <sub>
          Ca-T
         </sub>
         ) and late sodium (I
         <sub>
          Na
         </sub>
         ) currents and the outward potassium currents coming from the Kv7.1/I
         <sub>
          Ks
         </sub>
         (
         <em>
          KCNQ1
         </em>
         ) and the Kv11.1/I
         <sub>
          Kr
         </sub>
         (
         <em>
          KCNH2
         </em>
         ) potassium channels.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phase 3 (rapid repolarization)
         </strong>
         – Phase 3 represents the rapid repolarization that occurs when the outward potassium currents dominate over the decaying inward calcium current. Repolarization is predominantly mediated by the aforementioned outward potassium currents (I
         <sub>
          Ks
         </sub>
         and I
         <sub>
          Kr
         </sub>
         ). These channels open in response to depolarization and allow potassium to flow out of cells and repolarize the membrane potential toward its resting level, until activated
         <em>
          KCNJ2-
         </em>
         encoded Kir2.1 potassium channels (I
         <sub>
          K1
         </sub>
         ) drive and hold the membrane potential around -90 mV. The QT interval on the surface ECG is determined by the activity of these channels.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2054581009">
         <span class="h3">
          Prolonged repolarization and early afterdepolarizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prolongation of the QT interval increases the probability for EADs. EADs are single or multiple oscillations of the membrane potential that can occur during phase 2 or 3 of the action potential  (
         <a class="graphic graphic_figure graphicRef71390" href="/z/d/graphic/71390.html" rel="external">
          figure 2
         </a>
         ). EADs occur in association with prolongation of the repolarization phase of the action potential. If occurring in phase 2 of the action potential, EADs are thought to be caused by increased inward current through L-type calcium channels [
         <a href="#rid7">
          7
         </a>
         ] or through the sodium-calcium exchanger [
         <a href="#rid8">
          8
         </a>
         ]. Depolarizing currents occurring late in phase 3 are thought to be due to inward currents through T-type calcium channels or sodium channels [
         <a href="#rid9">
          9
         </a>
         ]. Pathologic prolongation of repolarization results most often from a decrease in the outward currents (LQT1 and LQT2) or increases in the sodium current (LQT3). (See
         <a class="medical medical_review" href="/z/d/html/895.html" rel="external">
          "Cardiac excitability, mechanisms of arrhythmia, and action of antiarrhythmic drugs", section on 'Triggered activity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1929766548">
         <span class="h3">
          Triggered activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Triggered responses or triggered activity are EADs that reach threshold potential, depolarize cell membranes, and result in additional action potentials. Propagation of these triggered responses produce ventricular premature depolarizations that may initiate LQTS' pathognomonic polymorphic ventricular tachycardia (VT), known as TdP, in susceptible individuals. EADs and triggered responses are particularly easy to induce in Purkinje fibers and M cells, a group of cells in the left ventricular free wall that have been identified as the site of EAD-induced triggered activity after exposure to drugs such as
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         [
         <a href="#rid10">
          10,11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2492585228">
         <span class="h3">
          Common precipitants of early afterdepolarizations and triggered activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of EADs is potentiated by bradycardia, hypokalemia, hypomagnesemia, and a long list of medications. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bradycardia
         </strong>
         – Slow heart rates are associated with increased inactivation of the outward repolarizing potassium current and a reduction in the Na-K-ATPase pump outward current (3 Na out/2 K in = net outward positive current). Slow heart rates also enhance the activity of certain antiarrhythmic drugs on repolarization (ie, repolarization and the QT interval are more prolonged). This property is called reverse use dependence and can lead to ion fluxes that facilitate EADs and TdP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypokalemia
         </strong>
         – Low potassium levels lead to a decreased outward repolarizing current via reductions in electrogenic Na-K-ATPase pump activity and outward potassium channel activity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3532594979">
         <span class="h2">
          Role of sympathetic activity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence supporting the significance of sympathetic activity in LQTS includes observations on the impact of the stellate ganglia. The left cardiac sympathetic nerves (left stellate ganglion and first four thoracic ganglia) are quantitatively dominant in terms of release of norepinephrine in the heart compared with the right-sided sympathetic nerves. In addition, the left-sided cardiac sympathetic nerves innervate primarily the posterior and left part of the ventricles [
         <a href="#rid12">
          12,13
         </a>
         ]. In addition, sympathetic stimulation can also facilitate the onset of ventricular arrhythmias, including triggered activity and early after depolarizations.
        </p>
        <p>
         Experimental studies have demonstrated that right stellectomy or stimulation of the left stellate ganglion both prolong the QT interval and alter T wave morphology in a manner that mimics the surface ECG found in patients with LQTS, including the induction of T wave alternans [
         <a href="#rid14">
          14
         </a>
         ]. Antiadrenergic therapies, including beta blockers and left cardiac sympathetic denervation (LCSD), substantially reduce the risk of TdP in patients with LQTS. Whereas beta blockers have a modest effect on the QT interval, LCSD shortens it significantly in most patients [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/988.html" rel="external">
          "Congenital long QT syndrome: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2881430398">
         <span class="h2">
          Dispersion of repolarization and re-entry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both the dispersion of repolarization and re-entry may be other potential mechanisms for the development of TdP. Dispersion of repolarization refers to an inhomogeneity in repolarization or recovery of excitability in a region of myocardium. A specific population of cells in the myocardium, called M cells, demonstrate marked prolongation of action potential duration in response to drugs such as
         <a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">
          quinidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">
          sotalol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         [
         <a href="#rid10">
          10,11
         </a>
         ]. Dispersion of repolarization could therefore occur in response to these drugs if the action potential is prolonged in M cells but not in the surrounding myocardium. The result is a functional block in the M cell region, providing the necessary milieu for the development of a reentrant arrhythmia [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3268880991">
         <span class="h2">
          Initiation and maintenance of torsades de pointes
         </span>
         <span class="headingEndMark">
          —
         </span>
         EADs and triggered activity are thought to be the most common initiating mechanism for the ventricular ectopy and TdP associated with long QT intervals [
         <a href="#rid16">
          16,17
         </a>
         ]. Alterations in sympathetic activity and dispersion of repolarization probably contribute to the electrophysiologic milieu that facilitates malignant arrhythmias, at least in certain cases.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TYPES OF CONGENITAL LQTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pathogenic variants in at least 17 genes have been identified thus far in patients with congenital LQTS  (
         <a class="graphic graphic_table graphicRef114927" href="/z/d/graphic/114927.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef120655" href="/z/d/graphic/120655.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. However, as clinical genetic testing evolves and the available data become more robust, some previously associated LQTS-susceptibility genes have been reclassified as having limited evidence or disputed evidence as LQTS-causative genes in terms of the strength of their disease-gene association [
         <a href="#rid18">
          18
         </a>
         ]. Additionally, the classifications and nomenclature are evolving, with the historical naming convention (LQT followed by the next number in sequence) being replaced by more descriptive names [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
         LQTS-causative variants in the three canonical genes,
         <em>
          KCNQ1
         </em>
         (LQT1; 35 to 40 percent),
         <em>
          KCNH2
         </em>
         (LQT2; 25 to 30 percent), and
         <em>
          SCN5A
         </em>
         (LQT3; 5 to 10 percent), account for at least 75 to 80 percent of all LQTS, with pathogenic variants in the minor LQTS-susceptibility genes contributing another 5 percent. (See
         <a class="medical medical_review" href="/z/d/html/128462.html" rel="external">
          "Gene test interpretation: Congenital long QT syndrome genes (
          <i>
           KCNQ1
          </i>
          ,
          <i>
           KCNH2
          </i>
          ,
          <i>
           SCN5A
          </i>
          )"
         </a>
         .)
        </p>
        <p>
         The remaining 15 to 20 percent of patients with an established clinical diagnosis of congenital LQTS will not have an identifiable genetic cause following clinically indicated contemporary genetic testing, and they are referred to as having either genetically elusive LQTS or genotype negative LQTS.
        </p>
        <p class="headingAnchor" id="H1745212368">
         <span class="h2">
          Canonical LQTS-causative genes
         </span>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Type 1 LQTS (LQT1)
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first association between a chromosomal marker and congenital LQTS was identified by analysis of a Utah family with a high prevalence of this disorder [
         <a href="#rid21">
          21
         </a>
         ]. Linkage was found between the LQTS phenotype and a marker on the short arm of chromosome 11. Investigators using positional cloning techniques identified the involved gene
         <em>
          KvLQT1,
         </em>
         which is now called
         <em>
          KCNQ1
         </em>
         [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         LQT1 accounts for up to 45 percent of cases of LQTS (35 to 40 percent in most countries and most cohorts) [
         <a href="#rid23">
          23
         </a>
         ]. Most patients with LQT1 show paradoxical prolongation of the QT interval during an exercise stress test, especially during the recovery phase of the stress test, which can be used to unmask patients with electrocardiographically concealed LQT1 [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p>
         The protein product of
         <em>
          KCNQ1
         </em>
         (Kv7.1 alpha-subunit), when coexpressed with the cardiac protein minK (IsK or beta-subunit, which is encoded by
         <em>
          KCNE1
         </em>
         ), forms the slowly acting component of the outward-rectifying potassium current (I
         <sub>
          Ks
         </sub>
         ) [
         <a href="#rid26">
          26-28
         </a>
         ]. Suppression of I
         <sub>
          Ks
         </sub>
         by loss-of-function variants in the
         <em>
          KCNQ1
         </em>
         gene in the absence or presence of minK can be correlated with and likely underlie prolongation of human ventricular action potentials [
         <a href="#rid29">
          29
         </a>
         ]. Pathogenic variants in the
         <em>
          KCNE1
         </em>
         -encoded minK (LQT5) produces a similar defect in I
         <sub>
          Ks
         </sub>
         (
         <a class="graphic graphic_figure graphicRef70771" href="/z/d/graphic/70771.html" rel="external">
          figure 3
         </a>
         ). Gain-of-function variants in
         <em>
          KCNQ1
         </em>
         have been associated with familial atrial fibrillation [
         <a href="#rid30">
          30
         </a>
         ] and with the congenital short QT syndrome, designated as type 2 short QT syndrome or SQT2 [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">
          "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Genetic factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16697.html" rel="external">
          "Short QT syndrome"
         </a>
         .)
        </p>
        <p>
         Many missense variants and some other types of loss-of-function variants have been identified in
         <em>
          KCNQ1
         </em>
         . The severity of the clinical features of LQT1 vary with the specific LQT1-causative variant [
         <a href="#rid32">
          32
         </a>
         ]. In particular, disease-causative variants localizing to the transmembrane region are associated with more frequent cardiac events (syncope, aborted cardiac arrest, or sudden cardiac death) than those variants that reside in the C-terminal region (55 versus 21 percent) [
         <a href="#rid33">
          33
         </a>
         ]. Variants close to A341V carry a higher risk for arrhythmic events [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         For example, one particular LQT1 variant (
         <em>
          KCNQ1
         </em>
         A341V) is associated with high clinical severity independent of ethnic origin [
         <a href="#rid34">
          34
         </a>
         ]. In a study comparing 244 patients with A341V with 205 patients with non-A341V LQT1 variants at a median follow-up of approximately 30 years, patients with LQT1-A341V were significantly more likely to have cardiac events (75 versus 24 percent), were younger at first event (6 versus 11 years), and had a longer QTc (485±43 versus 465±38 ms). Also, other LQT1-causative variants in proximity to A341V have been associated with a higher risk of arrhythmic events [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Homozygous loss-of-function variants in
         <em>
          KCNQ1
         </em>
         can cause the Jervell and Lange-Nielsen syndrome [
         <a href="#rid35">
          35,36
         </a>
         ]. Hearing loss can also be induced by the loss of functional minK protein, which seems to disrupt the production of endolymph. (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Congenital sensorineural deafness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Type 2 LQTS (LQT2)
         </span>
         <span class="headingEndMark">
          —
         </span>
         LQT2, which accounts for 25 to 40 percent of cases of congenital LQTS [
         <a href="#rid23">
          23,37,38
         </a>
         ], is caused by loss-of-function variants in a different potassium channel gene, localized to chromosome 7 [
         <a href="#rid39">
          39-41
         </a>
         ]. The disease-causative gene is called
         <em>
          KCNH2
         </em>
         (formerly
         <em>
          HERG
         </em>
         ), which encodes the Kv11.1 potassium channel that underlies the rapidly acting component of the outward-rectifying potassium current (I
         <sub>
          Kr
         </sub>
         )  (
         <a class="graphic graphic_figure graphicRef70771" href="/z/d/graphic/70771.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid42">
          42-45
         </a>
         ]. This current is largely responsible for repolarization and thus the QT interval duration. The
         <em>
          KCNH2-
         </em>
         encoded Kv11.1 channels have unique electrophysiologic features that may normally protect against early afterdepolarizations (EADs) [
         <a href="#rid44">
          44
         </a>
         ]. Most of the drugs that cause acquired/drug-induced QT prolongation block these Kv11.1 channels. (See
         <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">
          "Acquired long QT syndrome: Definitions, pathophysiology, and causes"
         </a>
         .)
        </p>
        <p>
         LQT2-causative variants span the entirety of the Kv11.1 channel [
         <a href="#rid41">
          41,46
         </a>
         ]. In a study of 201 patients, those with pathogenic variants localizing to the pore region had a significantly greater risk of a cardiac event (74 percent, versus 35 percent with variants in the non-pore region) and sudden cardiac death (SCD) or aborted cardiac arrest (15 versus 6 percent); these manifestations occurred at an earlier age in the patients with pore-localizing variants [
         <a href="#rid41">
          41
         </a>
         ]. Patients with a LQT2-causative variant in Kv11.1's pore had a significantly greater risk of a cardiac event at a QTc of 500 ms (hazard ratio 11); each 10 ms change in the QTc above or below 500 ms increased or decreased the risk by 16 percent.
        </p>
        <p>
         In some reports, non-pore variants are more likely to be associated with torsades de pointes (TdP) in the presence of hypokalemia [
         <a href="#rid46">
          46
         </a>
         ]. However, a malignant phenotype has been described in a family with a novel variant in the nonpore region [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
         In contrast to LQT2-associated loss-of-function variants in
         <em>
          KCNH2,
         </em>
         there are gain-of-function variants in
         <em>
          KCNH2
         </em>
         that result in accentuated I
         <sub>
          Kr
         </sub>
         activity. Patients with
         <em>
          KCNH2
         </em>
         gain-of-function variants are classified as SQT1. (See
         <a class="medical medical_review" href="/z/d/html/16697.html" rel="external">
          "Short QT syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Type 3 LQTS (LQT3)
         </span>
         <span class="headingEndMark">
          —
         </span>
         LQT3, which accounts for 5 to 10 percent of cases [
         <a href="#rid23">
          23,37,38
         </a>
         ], is caused by pathogenic variants in the sodium channel gene (
         <em>
          SCN5A
         </em>
         ) located on chromosome 3; many variants have been associated with LQT3 [
         <a href="#rid48">
          48,49
         </a>
         ]. The LQT3-causative variants result in gain-of-function by either increasing the late sodium current (like one of the originally discovered in-frame deletions, DeltaKPQ), increasing the window current through biophysical alterations of the kinetics of activation or inactivation, or through both mechanisms. One of the most interesting variants in
         <em>
          SCN5A
         </em>
         is the missense mutation, E1784K, which demonstrates most clearly the phenomenon of host-dependent disease expressivity, as E1784K is not only the most common LQT3-associated variant published to date but also the single most common
         <em>
          SCN5A
         </em>
         variant associated with a completely different genetic arrhythmia syndrome known as Brugada syndrome [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">
          "Brugada syndrome: Clinical presentation, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
         Similar to LQT1 and LQT2, sporadic (de novo)
         <em>
          SCN5A
         </em>
         variants have also been described in which neither parent had either the variant or a prolonged QT interval. In contrast to the heritable variants, one of these de novo variants resulted in a prolonged opening and early reopening of the sodium channel, and therefore a threefold prolongation of sodium current decay [
         <a href="#rid52">
          52
         </a>
         ]. Pathogenic variants in
         <em>
          SCN5A
         </em>
         have been associated with sudden infant death syndrome, at least some of which are sporadic [
         <a href="#rid53">
          53-55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Sudden infant death syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h4">
          Other disease-causative variants in SCN5A
         </span>
         <span class="headingEndMark">
          —
         </span>
         Different genetic variants in
         <em>
          SCN5A
         </em>
         can also cause a variety of other cardiac abnormalities, including Brugada syndrome, a related disorder, the sudden unexpected nocturnal death syndrome, an isolated familial atrioventricular conduction defect, congenital sinus node dysfunction, and familial dilated cardiomyopathy with conduction defects and susceptibility to atrial fibrillation. In addition, some pathogenic variants are associated with both LQT3 and the Brugada syndrome, with or without a conduction block [
         <a href="#rid56">
          56,57
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/106759.html" rel="external">
          "Brugada syndrome: Clinical presentation, diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
         The differences in clinical manifestations are probably due to differences in the electrophysiologic abnormalities induced by the specific variants [
         <a href="#rid58">
          58,59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1020.html" rel="external">
          "Brugada syndrome: Epidemiology and pathogenesis", section on 'Genetics'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/907.html" rel="external">
          "Etiology of atrioventricular block", section on 'Familial disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4911.html" rel="external">
          "Genetics of dilated cardiomyopathy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/940.html" rel="external">
          "Sinus node dysfunction: Epidemiology, etiology, and natural history", section on 'Childhood and familial disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1019.html" rel="external">
          "Approach to sudden cardiac arrest in the absence of apparent structural heart disease", section on 'Brugada syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Compound/multiple variant-mediated LQTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In different large series, 4.5 and 7.9 percent of unrelated individuals who were each the first in their families to be diagnosed with LQTS (probands) had two disease-causing variants [
         <a href="#rid60">
          60,61
         </a>
         ]. This unexpectedly high incidence of compound variants could be a reflection of selection bias, since such individuals would be more likely to develop clinical disease. (See
         <a class="medical medical_review" href="/z/d/html/1036.html" rel="external">
          "Congenital long QT syndrome: Epidemiology and clinical manifestations", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         Consistent with this hypothesis is the observation that patients with multiple variants, compared with those with only one variant, have significantly longer QT intervals and are more likely to experience a life-threatening cardiac arrhythmia [
         <a href="#rid61">
          61,62
         </a>
         ].
        </p>
        <p>
         The presence of &gt;1 pathogenic variant can also affect the success of genetic testing. (See
         <a class="local">
          'Genetic testing'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3890751915">
         <span class="h2">
          Minor LQTS-susceptibility genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since the discovery of the three canonical LQTS-causative genes in the 1980s and 1990s, up to 14 additional, albeit minor, LQTS-susceptibility genes have been discovered by either hypothesis-driven candidate gene research or genomic triangulation strategies using whole exome sequencing [
         <a href="#rid19">
          19
         </a>
         ]. The LQTS genotypes stemming from these minor genes  (
         <a class="graphic graphic_table graphicRef114927" href="/z/d/graphic/114927.html" rel="external">
          table 1
         </a>
         ) have been annotated in the past as LQT4-17. However, these subtypes are best described by their gene, such as
         <em>
          CACNA1C
         </em>
         -LQTS (instead of LQT8) and TRDN-LQTS (instead of LQT17). Some of these minor genetic subtypes converge upon the final common pathway of one of the canonical subtypes. For example, LQT5 (preferred name:
         <em>
          KCNE1
         </em>
         -LQTS) mimics LQT1, while
         <em>
          CAV3
         </em>
         -LQTS results in accentuation of the late sodium current akin to primary variants in
         <em>
          SCN5A
         </em>
         (LQT3).
        </p>
        <p>
         The most common of the minor LQTS-susceptibility genes is probably
         <em>
          CACNA1C-
         </em>
         mediated LQTS (previously called LQT8) [
         <a href="#rid63">
          63
         </a>
         ].
         <strong>
         </strong>
         Gain-of-function variants in
         <em>
          CACNA1C
         </em>
         -encoded Cav1.2 were first discovered in a complex multisystem disorder called Timothy syndrome, which included marked QT prolongation [
         <a href="#rid64">
          64
         </a>
         ]. More recently, however, other
         <em>
          CACNA1C
         </em>
         variants have been associated with cardiac-only, autosomal dominant LQTS.
        </p>
        <p>
         Among all of the minor LQTS-susceptibility genes, the most penetrant ones have involved either autosomal dominant or sporadic de novo variants in one of the three
         <em>
          CALM
         </em>
         genes that encode the 100 percent identical 103 amino-acid-containing calmodulin proteins or homozygous/compound heterozygous, autosomal recessive inherited variants in
         <em>
          TRDN-
         </em>
         encoded triadin [
         <a href="#rid65">
          65,66
         </a>
         ]. The CALM1-3-LQTS subtypes are referred to collectively as the calmodulinopathies, since the phenotype overlaps with not only LQTS but also catecholaminergic polymorphic ventricular tachycardia [
         <a href="#rid67">
          67
         </a>
         ]. These are listed in an International Calmodulinopathy Registry [
         <a href="#rid68">
          68
         </a>
         ]. Similarly, patients with autosomal recessive loss-of-function variants in
         <em>
          TRDN
         </em>
         are referred to as having Triadin Knockout Syndrome (TKOS) because of phenotypic overlap; there is an International TKOS Registry to enroll patients with this severe channelopathy [
         <a href="#rid68">
          68
         </a>
         ]. Children with these severe forms of disease (calmodulinopathies and TKOS) continue to experience breakthrough cardiac events despite receiving optimal guideline-directed LQTS therapies.
        </p>
        <p class="headingAnchor" id="H4276415147">
         <span class="h1">
          GENETIC TESTING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical genetic testing is standard of care to identify LQTS-causative variants in any patient for which a clinical diagnosis of LQTS is being contemplated [
         <a href="#rid69">
          69-72
         </a>
         ]. However, such testing is subject to limitations given the complexity and heterogeneity of the disorder. It has been estimated that a specific LQTS-causative variant in one of the three canonical genes (
         <em>
          KCNQ1
         </em>
         ,
         <em>
          KCNH2
         </em>
         , and
         <em>
          SCN5A
         </em>
         ) will be identified in at least 75 to 80 percent of patients who express a robust phenotype consistent with the diagnosis of LQTS [
         <a href="#rid23">
          23
         </a>
         ]. Approximately 4 percent of controls have a rare variant of uncertain significance (in
         <em>
          KCNQ1, KCNH2,
         </em>
         or
         <em>
          SCN5A
         </em>
         ), which represents a lower point estimate for the potential false positive rate for genetic testing [
         <a href="#rid73">
          73,74
         </a>
         ].
        </p>
        <p>
         In a series of 541 unrelated patients from the Mayo Clinic, the overall yield of genetic testing was approximately 50 percent and correlated with clinical measures of disease severity [
         <a href="#rid75">
          75
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The likelihood of identifying a pathogenic variant increased progressively with increasing QTc, ranging from 0 to 62 percent as the QTc increased from the lowest (&lt;400 ms) to the highest (&gt;480 ms) category.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A clinical LQTS diagnostic tool that predicts the likelihood of LQTS, the Schwartz LQTS score, is derived from the QTc, symptoms, and family history [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with a Schwartz LQTS score ≥4, suggesting a strong probability of LQTS, had a disease-causative variant identified more frequently than those with a score &lt;4 (72 versus 44 percent). (See
         <a class="medical medical_review" href="/z/d/html/1053.html" rel="external">
          "Congenital long QT syndrome: Diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Additional information on the approach to a genetic test result is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/128462.html" rel="external">
          "Gene test interpretation: Congenital long QT syndrome genes (
          <i>
           KCNQ1
          </i>
          ,
          <i>
           KCNH2
          </i>
          ,
          <i>
           SCN5A
          </i>
          )"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1298416660">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">
          "Society guideline links: Arrhythmias in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/116416.html" rel="external">
          "Society guideline links: Inherited arrhythmia syndromes"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1651940514">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86973.html" rel="external">
          "Patient education: Long QT syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19875495">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Genetic variants
         </strong>
         – At least 17 congenital long QR syndrome (LQTS)-susceptibility genes have been identified  (
         <a class="graphic graphic_table graphicRef114927" href="/z/d/graphic/114927.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Types of congenital LQTS'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         LQT1, LQT2, and LQT3 account for approximately 75 to 80 percent of cases of congenital LQTS.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The minor LQTS-susceptibility genes account for &lt;5 percent of LQTS. Some are associated with distinct clinical syndromes (eg,
         <em>
          CALM1-3-
         </em>
         mediated LQTS is called calmodulinopathy;
         <em>
          TRDN-
         </em>
         mediated LQTS is triadin knockout syndrome [TKOS]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQT1
         </strong>
         – This accounts for up to 45 percent of cases of the LQTS and is caused by loss-of-function variants in the
         <em>
          KCNQ1-
         </em>
         encoded Kv7.1 potassium channel.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Most patients show paradoxical prolongation of the QT interval during the recovery phase after treadmill stress testing, which can be used to unmask patients with otherwise electrocardiographically (ECG) concealed LQT1.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Events triggered by exercise, particularly swimming, are characteristic of (but not specific for) LQT1. (See
         <a class="local">
          'Type 1 LQTS (LQT1)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQT2
         </strong>
         – This accounts for 25 to 40 percent of cases of congenital LQTS and is caused by a variety of loss-of-function variants in the
         <em>
          KCNH2
         </em>
         -encoded Kv11.1 potassium channels. Intragenic risk stratification is possible; as an example, patients with LQT2-causative variants localizing to Kv11.1's pore have worse clinical outcomes than those with pathogenic variants localizing the channel's C-terminal region.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQT3
         </strong>
         – This accounts for 5 to 10 percent of cases and is caused by gain-of-function variants in the
         <em>
          SCN5A-
         </em>
         encoded Nav1.5 sodium channel. Events occurring at rest or during sleep are characteristic of (but not specific for) LQT3. (See
         <a class="local">
          'Type 3 LQTS (LQT3)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          LQTS genetic testing
         </strong>
         – This has been available clinically/commercially since 2004 in the United States, and LQTS genetic testing is a class I recommendation for any patient being considered to have LQTS to enable genotype-guided risk stratification and genotype-guided tailoring of therapy and to permit cascade variant-specific testing of the appropriate relatives. (See
         <a class="local">
          'Genetic testing'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Ackerman MJ. The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 2013; 34:3109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ. Long QT Syndrome. JAMA 2003; 289:2041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Sherif N, Turitto G. Torsade de pointes. Curr Opin Cardiol 2003; 18:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am 2001; 85:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Ackerman MJ, George AL Jr, Wilde AAM. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013; 62:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res 1989; 64:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szabo B, Sweidan R, Rajagopalan CV, Lazzara R. Role of Na+:Ca2+ exchange current in Cs(+)-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol 1994; 5:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Antzelevitch C, Sun ZQ, Zhang ZQ, Yan GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28:1836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-David J, Zipes DP. Torsades de pointes and proarrhythmia. Lancet 1993; 341:1578.
          </a>
         </li>
         <li class="breakAll">
          Schwartz P, Locati E, Priori E, Zaza A. Cardiac Electrophysiology: From Cell to Bedside. In: Cardiac Electrophysiology: From Cell to Bedside, Zipes D, Jalife J (Eds), WB Saunders, Philadelphia 1990. p.589.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975; 89:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dusi V, Pugliese L, De Ferrari GM, et al. Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management. JACC Clin Electrophysiol 2022; 8:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan HL, Hou CJ, Lauer MR, Sung RJ. Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan GX, Wu Y, Liu T, et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103:2851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hosseini SM, Kim R, Udupa S, et al. Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. Circulation 2018; 138:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giudicessi JR, Wilde AAM, Ackerman MJ. The genetic architecture of long QT syndrome: A critical reappraisal. Trends Cardiovasc Med 2018; 28:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giudicessi JR, Roden DM, Wilde AAM, Ackerman MJ. Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation 2018; 137:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackman WM, Friday KJ, Anderson JL, et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 2011; 8:1308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Khositseth A, Tester DJ, et al. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc 2002; 77:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimizu W, Noda T, Takaki H, et al. Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol 2003; 41:633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barhanin J, Lesage F, Guillemare E, et al. K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature 1996; 384:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanguinetti MC, Curran ME, Zou A, et al. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature 1996; 384:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splawski I, Tristani-Firouzi M, Lehmann MH, et al. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet 1997; 17:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shalaby FY, Levesque PC, Yang WP, et al. Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome. Circulation 1997; 96:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003; 299:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bellocq C, van Ginneken AC, Bezzina CR, et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004; 109:2394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Moreno C, Kotta MC, et al. Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region. Eur Heart J 2021; 42:4743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shimizu W, Horie M, Ohno S, et al. Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol 2004; 44:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crotti L, Spazzolini C, Schwartz PJ, et al. The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification. Circulation 2007; 116:2366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           JERVELL A, LANGE-NIELSEN F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 1957; 54:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Spazzolini C, Crotti L, et al. The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome. Circulation 2006; 113:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splawski I, Shen J, Timothy KW, et al. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000; 102:1178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang C, Atkinson D, Towbin JA, et al. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet 1994; 8:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furutani M, Trudeau MC, Hagiwara N, et al. Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation 1999; 99:2290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ, Zareba W, Kaufman ES, et al. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation 2002; 105:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller C. The inconstancy of the human heart. Nature 1996; 379:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng GN. I(Kr): the hERG channel. J Mol Cell Cardiol 2001; 33:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berthet M, Denjoy I, Donger C, et al. C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence. Circulation 1999; 99:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rossenbacker T, Mubagwa K, Jongbloed RJ, et al. Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome. Circulation 2005; 111:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei J, Wang DW, Alings M, et al. Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation 1999; 99:3165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009; 6:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kambouris NG, Nuss HB, Johns DC, et al. Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel. Circulation 1998; 97:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med 2000; 343:262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wedekind H, Smits JP, Schulze-Bahr E, et al. De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation 2001; 104:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Siu BL, Sturner WQ, et al. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA 2001; 286:2264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant AO, Carboni MP, Neplioueva V, et al. Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. J Clin Invest 2002; 110:1201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy CE, Rudy Y. Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 2002; 105:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deschênes I, Baroudi G, Berthet M, et al. Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes. Cardiovasc Res 2000; 46:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clancy CE, Kass RS. Defective cardiac ion channels: from mutations to clinical syndromes. J Clin Invest 2002; 110:1075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Napolitano C, Priori SG, Schwartz PJ, et al. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA 2005; 294:2975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westenskow P, Splawski I, Timothy KW, et al. Compound mutations: a common cause of severe long-QT syndrome. Circulation 2004; 109:1834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mullally J, Goldenberg I, Moss AJ, et al. Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations. Heart Rhythm 2013; 10:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boczek NJ, Best JM, Tester DJ, et al. Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome. Circ Cardiovasc Genet 2013; 6:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reed GJ, Boczek NJ, Etheridge SP, Ackerman MJ. CALM3 mutation associated with long QT syndrome. Heart Rhythm 2015; 12:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altmann HM, Tester DJ, Will ML, et al. Homozygous/Compound Heterozygous Triadin Mutations Associated With Autosomal-Recessive Long-QT Syndrome and Pediatric Sudden Cardiac Arrest: Elucidation of the Triadin Knockout Syndrome. Circulation 2015; 131:2051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boczek NJ, Gomez-Hurtado N, Ye D, et al. Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G. Circ Cardiovasc Genet 2016; 9:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clemens DJ, Tester DJ, Giudicessi JR, et al. International Triadin Knockout Syndrome Registry. Circ Genom Precis Med 2019; 12:e002419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wehrens XH, Vos MA, Doevendans PA, Wellens HJ. Novel insights in the congenital long QT syndrome. Ann Intern Med 2002; 137:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999; 99:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li H, Fuentes-Garcia J, Towbin JA. Current concepts in long QT syndrome. Pediatr Cardiol 2000; 21:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priori SG, Barhanin J, Hauer RN, et al. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. Circulation 1999; 99:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Tester DJ, Jones GS, et al. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc 2003; 78:1479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm 2004; 1:600.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tester DJ, Will ML, Haglund CM, Ackerman MJ. Effect of clinical phenotype on yield of long QT syndrome genetic testing. J Am Coll Cardiol 2006; 47:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993; 88:782.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1009 Version 36.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23509228" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12709446" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Long QT Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12496496" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11233951" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23684683" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Impact of genetics on the clinical management of channelopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27150690" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2468430" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7889233" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Role of Na+:Ca2+ exchange current in Cs(+)-induced early afterdepolarizations in Purkinje fibers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873679" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8277090" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Clinical relevance of cardiac arrhythmias generated by afterdepolarizations. Role of M cells in the generation of U waves, triggered activity and torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8962574" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8099651" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Torsades de pointes and proarrhythmia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8099651" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Torsades de pointes and proarrhythmia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1109551" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35331422" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Left Cardiac Sympathetic Denervation for Long QT Syndrome: 50 Years' Experience Provides Guidance for Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7702233" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11401944" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29959160" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Reappraisal of Reported Genes for Sudden Arrhythmic Death: Evidence-Based Evaluation of Gene Validity for Brugada Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29661707" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The genetic architecture of long QT syndrome: A critical reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29431662" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3047813" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8528244" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21787999" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12004990" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12598076" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8900282" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8900283" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9354802" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mutations in the hminK gene cause long QT syndrome and suppress IKs function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9323054" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Dominant-negative KvLQT1 mutations underlie the LQT1 form of long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12522251" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : KCNQ1 gain-of-function mutation in familial atrial fibrillation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15159330" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mutation in the KCNQ1 gene leading to the short QT-interval syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34505893" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Mutation location and IKs regulation in the arrhythmic risk of long QT syndrome type 1: the importance of the KCNQ1 S6 region.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15234419" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984373" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13435203" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16461811" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Jervell and Lange-Nielsen syndrome: natural history, molecular basis, and clinical outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10973849" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136691" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7842012" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10226095" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854117" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7889573" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7736582" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8587597" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The inconstancy of the human heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11343409" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : I(Kr): the hERG channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10086971" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : C-terminal HERG mutations: the role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15699249" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Novel mutation in the Per-Arnt-Sim domain of KCNH2 causes a malignant form of long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7889574" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10377081" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19716085" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20129283" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9495298" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Phenotypic characterization of a novel long-QT syndrome mutation (R1623Q) in the cardiac sodium channel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10911008" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A molecular link between the sudden infant death syndrome and the long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11535573" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : De novo mutation in the SCN5A gene associated with early onset of sudden infant death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11710892" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393856" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11889015" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Na(+) channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10727653" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Electrophysiological characterization of SCN5A mutations causing long QT (E1784K) and Brugada (R1512W and R1432G) syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393842" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Defective cardiac ion channels: from mutations to clinical syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16414944" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051636" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Compound mutations: a common cause of severe long-QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23174487" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Risk of life-threatening cardiac events among patients with long QT syndrome and multiple mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23677916" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Exome sequencing and systems biology converge to identify novel mutations in the L-type calcium channel, CACNA1C, linked to autosomal dominant long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12193783" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25460178" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : CALM3 mutation associated with long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25922419" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Homozygous/Compound Heterozygous Triadin Mutations Associated With Autosomal-Recessive Long-QT Syndrome and Pediatric Sudden Cardiac Arrest: Elucidation of the Triadin Knockout Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26969752" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Spectrum and Prevalence of CALM1-, CALM2-, and CALM3-Encoded Calmodulin Variants in Long QT Syndrome and Functional Characterization of a Novel Long QT Syndrome-Associated Calmodulin Missense Variant, E141G.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30649896" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : International Triadin Knockout Syndrome Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12484714" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Novel insights in the congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9927398" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11050278" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Current concepts in long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9950666" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14661677" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15851227" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16487842" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Effect of clinical phenotype on yield of long QT syndrome genetic testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8339437" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Diagnostic criteria for the long QT syndrome. An update.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
